Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Device Approval”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,567 records · Page 87Linked to original sources

Recent medical-legal proceedings and their effect on the practice of medicine in Chicago.

Since January 1994, northern Illinois has experienced a significant increase in litigation, which has been directly related to the lack of FDA approval of pedicle screw devices, and the adverse media attention to the FDA's actions. These activities coupled with those of the Public Citizen Health Research Group's have had a chilling effect on the practice of medicine. This is unwarranted, Congress has never provided the FDA with the authority to regulate the practice of medicine; and the FDA has reiterated that it lacks the intent or ability for such regulation. Medical science continues to outpace the regulatory process, and therefore it will remain the science of medicine that determines the standard of care.

Chicago↗

Vena cava filters: available devices and current practices.

Deep venous thrombosis and pulmonary embolus are significant clinical problems. Although anticoagulation remains first-line therapy for thromboembolic disease, the placement of inferior vena cava filters plays an important role as alternative or supplemental therapy. Initial filters were high-profile devices intended to be placed via surgical cutdown. Concerns about the size of the delivery systems prompted development of low-profile systems intended specifically for percutaneous placement. The placement of filters has progressively become a percutaneous procedure performed by interventional radiologists outside of the operating room. This article reviews the currently available devices that have been approved by the Food and Drug Administration, their indications, efficacy, and complications. Experimental temporary filter designs are discussed as well.

Equipment Design↗

Performance characteristics for an immunoassay.

In the United States of American the medical device amendments of 1976 established a comprehensive system for regulation of medicaldevices intended for human use. One provision of the amendmentsestablishes three categories (classes) of devices depending on the regulatory controls needed to provide reasonable assurance of safety and effectiveness. The categories are as follows: Class I, General Controls; Class II, Performance Standards; and Class III, Premarket Approval. The performance characteristics of an immunology device that requires premarket approval (CLASS III) may be viewed as an extension of successfully completed scientific and laboratory investigations. Clinical trials of the device establish analyte levels in well-defined populations of healthy and diseased individuals and provide an estimate of the central tendency of analyte range. The performance characteristics of an immunoassay kit are established by laboratory studies, these studies include but are not limited to the following studies: reproducibility, recovery, linearity, stability, specificity, and sensitivity.

Antibodies↗

Independence(TM) iBOT(TM) 3000 Mobility System: a stair-climbing wheelchair.

Independence (TM) iBOT(TM) 3000 is a wheelchair that may be used to climb stairs, elevate the user to standing adult eye level and cross uneven terrain. Limited evidence indicates that the device may offer more mobility and freedom to users than conventional wheelchairs. The iBOT may be difficult to manoeuvre indoors due to the seat height, but it operates well outdoors. The use of this technology is limited by the high cost of ownership and uncertain incremental benefit for users. While the device is not yet licensed for use in Canada, it is approved by the Food and Drug Administration for use in the US.

Activities of Daily Living↗

[Evaluation of hemodialysis systems (author's transl)].

Since March 1973, approval procedure for hemodialysis systems devices is mandatory in France. Basically it controls the minimum requirements to insure the effective, safe performance of these devices in the treatment of end stage renal disease. They include dialysing fluid systems, monitoring equipment and dialyzers. We have controlled 28 dialysate delivery system monitors and 21 dialyzer models. During the approval procedure a high rate of cases which do not meet the minimal requirements, were observed: 61 p. cent for the identification of the device, 72 p. cent for the safe electrical current limits (French National Standard), 83 p. cent for the monitoring and 22 p. cent for the duration (1,000 hours for center utilisation, 1,500 hours for home utilisation). Better results were found with dialyzer performances. Ultrafiltration flow rate and solute dialysance measured in vitro under clinical conditions of flow rates and pressures correlated well with the values claimed by the manufacturers. Problems encountered during the approval procedure stemmed from the lack of National and International Standard for hemodialysis systems and the poor compliance of the manufacturers to "good manufacturing practice" rules.

Clinical Trials as Topic↗

Implantable bone conduction hearing device: Audiant bone conductor. Update on our experiences.

An implantable hearing device has been developed and has undergone testing by animal experimentation and clinical trials in humans. Recently, the Food and Drug Administration has approved the use of this device in adults who are within the criteria of its utilization, mainly patients with conductive hearing impairments who have good inner ear reception and who are unable to benefit from surgical correction. This update describes observations and experiences we have had during the device's development and defines its limitations as well as its unique thrust into the future relief of hearing impairment. Clinical trials during the investigational period and engineering problems as well as progress are thoroughly discussed.

Adolescent↗

The Presbyterian-University Hospital, Pittsburgh. The gamma knife: brain surgery without an incision.

In July of 1987 a 20-ton gamma heavily shielded in a concrete "hot cell" was rolled into the basement of Presbyterian-University Hospital in Pittsburgh. Installation of the unit-one of only five in the world-and the first of its kind in the United States-was the culmination of 4.5 years of planning. It started in 1982 when the gamma knife was approved for marketing by the Food and Drug Administration. But because radioactive sources are sealed within the unit, it also had to be approved by the Nuclear Regulatory Commission (NRC), a process that required extensive and multiple levels of review within the nuclear agency. Although the device itself finally received NRC approval in 1986, the NRC Transportation Division refused to grant permission to transport a cobalt-loaded unit. So physicists at the University of Pittsburgh devised plans for on-site loading amidst the busy hospital environment in Pittsburgh! First a hot cell consisting of 3,000 lb of solid concrete block was constructed around the unit. Then, using robotic micromanipulators, the unit was loaded with 201 sources of cobalt-60, approximately 30 Ci each. The almost-6,000 Ci of cobalt provided a dosage rate of 396 cGy/min to the focal point, and patient treatment began one month later in August. Third-party reimbursement has been obtained from most major health insurance policies, and the procedure is approved for payment by Blue Shield and Medicare of Pennsylvania.

Brain Neoplasms↗

U.S. Food and Drug Administration and regulation of medical devices in radiology.

The recent decision by the U.S. Food and Drug Administration (FDA) to approve one ultrasound imaging system for use in making breast biopsy decisions prompted considerable interest in the radiology community about the regulatory process and the associated implications for the practice of medicine. In this report, the concepts and statutory authority guiding the FDA in the regulation of medical devices are summarized and discussed, including the device classification scheme, premarket approval, premarket notification, and investigational device exemptions. Also, the critical concepts of safety and effectiveness for a given indication for use, the roles of advisory panels, and examples of imaging and interventional devices are described to shed light on the approval process.

Consumer Product Safety↗

Device costs go under the knife. With four hospitals having won HHS' approval for gain-sharing to shave supply costs, some observers say it's just the beginning.

HHS' inspector general's office recently had some good news for four hospitals--they can use gain-sharing programs to help cut spending on devices. Joane Goodroe, left, is the consultant who helped the facilities devise proposals with safeguards that could satisfy the feds' worries about violating antikickback laws. "This is about paying physicians to take on the extra job of of reducing costs," Goodroe says.

Cardiology↗

Indications for long-term assist device placement as bridge to transplantation.

The current indications for long-term mechanical support as bridge to transplantation first require the patient to be a transplant candidate. Often times a patient presents with limited history and refractory cardiogenic shock, where a full transplant work-up for contraindications cannot be safely performed. The use of short-term mechanical support can be used to help filter out many patients who have easily identifiable contraindications to heart transplant. Nevertheless, patients need to be listed for a heart transplant before the implantation of some of these devices. This paradigm needs to be altered, because there are many instances where mechanical support can be used to support a patient for an intervention to "make" them a transplant candidate where they otherwise would not have been. Long-term mechanical support can overcome the cardiac contraindication to the surgical/interventional therapy to "cure" them of the process that would have prevented them from being a good cardiac transplant candidate in the first place. Noncardiac surgical procedures are well tolerated in these patients [11]. The FDA is currently evaluating the Vented Electric Heartmate system for use as destination therapy for patients who are not transplant candidates. Approval for this indication (with a device that is already approved for bridge to transplantation) will allow this paradigm shift. This system could be used in the group who may be good candidates, but not determined. If they were subsequently determined to not be a good surgical candidate, they would be chronically supported with the LVAD as destination therapy.

Equipment Design↗

Transcatheter devices used in the management of patients with congenital heart disease.

The availability of transcatheter devices has revolutionized the management of patients with congenital heart and vascular disease. Many patients that were in the past exclusively treated through open heart surgical procedures can now be managed using a percutaneous approach. This article describes those devices that are, at present, most frequently used in the USA for transcatheter therapy of congenital heart disease, which have, or are about to receive, US premarket approval. It also focuses on devices for occlusion of septal defects and vascular structures, as well as endovascular stents. In addition, the most important outcome data are discussed.

Cardiac Catheterization↗

Effect of challenging neck anatomy on mid-term migration rates in AneuRx endografts.

OBJECTIVE: To establish the effect of challenging neck anatomy on the mid- and long-term incidence of migration with the AneuRx bifurcated device in patients treated after Food and Drug Administration approval and to identify the predictive factors for device migration. METHODS: Prospectively maintained databases at the University of North Carolina (UNC) and Washington University (WU) were used to identify 595 patients (UNC, n = 230; WU, n = 365) who underwent endovascular repair of an infrarenal abdominal aortic aneurysm with the AneuRx bifurcated stent graft. Those patients with at least 30 months of follow-up were identified and underwent further assessment of migration (UNC, n = 25; WU, n = 59) by use of multiplanar reconstructed computed tomographic scans. RESULTS: Eighty-four patients with a mean follow-up time of 40.3 months (range, 30-55 months) were studied. Seventy percent of the patients (n = 59) met all inclusion criteria for neck anatomy (length, angle, diameter, and quality) as defined by the revised instructions for use guidelines and are referred to as those with favorable neck anatomy (FNA). The remaining 25 patients retrospectively fell outside of the revised instructions for use guidelines and are referred to as those with unfavorable neck anatomy (UFNA). Life-table analysis for FNA patients at 2 and 4 years revealed a migration rate of 0% and 6.1%, respectively. For UFNA patients, it was 24.0% and 42.1% at 2 and 4 years, respectively (P < .0001). The overall (FNA and UFNA) migration rate was 7.1% and 17.1% at 2 and 4 years, respectively. Overall, late graft-related complications occurred in 38% of patients (FNA, 27%; UFNA, 64%; P = .003; relative risk, 1.7). There was no incidence of late rupture or open conversion. The relative risk of migration for UFNA patients was 2.5 compared with FNA patients (P = .0003). A larger neck angle and a longer initial graft to renal artery distance were predictors of migration, whereas shorter neck length approached but did not reach statistical significance. CONCLUSIONS: Patients who have unfavorable aneurysm neck anatomy experience significantly higher migration, device-related complication, and secondary intervention rates. However, there was no incidence of open conversion, rupture, or abdominal aortic aneurysm-related death, thereby supporting the AneuRx device as a feasible alternative to open repair even in patients with challenging neck characteristics. Enhanced surveillance should be used in these high-risk patients.

Aged↗

Endovascular treatment of thoracic aortic aneurysms: results of the phase II multicenter trial of the GORE TAG thoracic endoprosthesis.

OBJECTIVE: A decade after the first report of descending thoracic aortic aneurysm (DTA) repair with endografts, a commercial device is yet to be approved in the United States. The GORE TAG endoprosthesis, an investigational nitinol-supported expanded polytetrafluoroethylene tube graft with diameters of 26 to 40 mm, is the first DTA device to enter phase II trials in the United States and has been used worldwide for a host of thoracic pathologies. METHODS: A multicenter prospective nonrandomized phase II study of the GORE TAG endoprosthesis was conducted at 17 sites. Enrollment was from September 1999 to May 2001. Preoperative workup included arteriography and spiral computed tomography scans of the chest, abdomen, and pelvis. Follow-up radiographs and computed tomography scans were obtained at 1, 6, and 12 months and yearly thereafter. RESULTS: A total of 139 (98%) of 142 patients had a successful implantation of the device. Inadequate arterial access was responsible for the 3 failures. The mean DTA size was 64.1 +/- 15.4 mm. Men slightly outnumbered women (57.7%), with an average age of 71 years, and 88% of the patients were white. Ninety percent were American Society of Anesthesiologists category III or IV. One device was used in 44% of patients, and 56% required two or more devices to bridge the thoracic aorta. The left subclavian artery was covered in 28 patients, with planned carotid-subclavian transposition. The procedure time averaged 150 minutes, estimated blood loss averaged 506 mL, intensive care unit stay averaged 2.6 days, and hospital stay averaged 7.6 days. Within 30 days, 45 (32%) patients had at least 1 major adverse event: 5 (4%) experienced a stroke, 4 (3%) demonstrated temporary or permanent paraplegia, 20 (14%) experienced vascular trauma or thrombosis, and 2 (1.5%) died. Mean follow-up was 24.0 months. Four patients had aneurysm-related deaths. Three patients underwent endovascular revisions for endoleak. No ruptures have been reported. Twenty wire fractures have been identified in 19 patients; 18 (90%) of these occurred in the longitudinal spine, and only 1 patient required treatment. At 2 years, aneurysm-related and overall survival rates are 97% and 75%, respectively. CONCLUSIONS: The GORE TAG thoracic endoprosthesis provides a safe alternative for the treatment of DTAs, with low mortality, relatively low morbidity, and excellent 2-year freedom from aneurysm-related death. Longitudinal spine fractures have so far been associated with rare clinical events.

Adult↗

Does skin cholesterol testing provide benefit?

Cholesterol 1,2,3 9 (TM) is being promoted as a non-invasive way to measure cholesterol that has accumulated in a person's skin. The test received a medical device licence from Health Canada in January 2001. It was approved by the U.S. Food and Drug Administration (FDA) in June 2002. This test is not intended to be used as a screening tool for coronary artery disease in the general population. Evidence from non-randomized, non-blinded clinical trials suggests a correlation between higher skin cholesterol levels and the presence of severe coronary arterial lesions. At this point, technical improvements and more robust evidence are required to determine the significance of this technology in clinical practice.

Canada↗

Catheter closure of atrial septal and ventricular septal defects using the Amplatzer devices.

The Amplatzer Septal Occluder (ASO) is a device that combines the advantages of being a double-disc with a self-centering mechanism. It is the first and only device to ever receive full approval for clinical use in children and adults with secundum atrial septal defects (AD) from the United States Food and Drug Administration. It has been used successfully to close secundum ASDs, patent foramen avale and Fontan fenestrations. The first patient to undergo closure with the ASO was approximately 6 years ago. So far the mid-term results are very encouraging with no long-term complications for the presence of the device. Complications encountered with the use of the Amplatzer septal occluder are rare and most may be managed in the catheter laboratory. Most of the complications occur in the immediate period post-implantation. The Amplatzer muscular and membranous ventricular septal defect devices are still undergoing clinical trials in the United States; however, they are fully approved in many countries. Long-term results about safety and efficacy, as well as results involving larger defects are being collected.

Journal Article↗

Intermediate-term results of Phase I Food and Drug Administration Trials of buttoned device occlusion of secundum atrial septal defects.

OBJECTIVES: This study was conducted to evaluate the intermediate-term results of the multi-institutional U.S. trial of the buttoned device for transcatheter closure of atrial septal defects (ASDs). BACKGROUND: The trial was conducted in three centers (University of Arizona, University of Michigan and University of Wisconsin) under a Food and Drug Administration (FDA)-approved clinical trial with investigational device exemption. Only short-term follow-up is known. METHODS: All 46 patients who had successful implantation of the device were prospectively followed up. Patients were evaluated at 1, 6 and 12 months after device occlusion and yearly thereafter. RESULTS: This cohort was followed up from 51 to 68 months (mean 60.8, median 62). Patient ages ranged from 1 to 62 years (median 4); weights ranged from 10 to 105 kg (median 18); and stretched ASD sizes were 14 +/- 4 mm (left to right shunts) and 10 +/- 3 mm (right to left shunts). Of the 46 patients, 45 (98%) had effective occlusion of their ASD, and 34 (74%) had complete ASD closure. The incidence of residual shunts decreased from 65% (30 of 46 patients) at 1 month after device placement to 27% (12 of 45 patients) at last follow-up. All residual shunts were quantitated as trivial. Only two patients (4%) required reintervention for significant residual defects. There were no cases of endocarditis or thromboembolism in 224 patient-years of follow-up. CONCLUSIONS: In up to 5.5 years of follow-up, the buttoned device provided effective closure in 98% of patients in whom the device was successfully implanted. The incidence of residual shunts decreased during follow-up, and no instances of endocarditis or thromboembolism were observed.

Actuarial Analysis↗

Designing medical devices for conformance with harmonized standards. The European Community's Medical Devices Directives and their effect on the product development process.

The European Community's Medical Devices Directives represent an ambitious effort to streamline the regulation of medical devices within the European Economic Area, and area comprising more than 380 million people. In this, the first of two special reports, Richard C. Fries and Mark D. Graber describe the Medical Devices Directives and their effect on the product development process. In the second report, appearing on page 294 Jean A. Goggins uses a case study format to demonstrate the process that would be used to gain European approval for a hypothetical medical device.

Biomedical Engineering↗

Computer-enhanced robotic telesurgery. Initial experience in foregut surgery.

BACKGROUND: A new type of computer-enhanced telemanipulator device for "robotic" laparoscopic surgery was recently approved. We prospectively evaluated the initial patients undergoing procedures with this new device at our institution. METHODS: Patient demographics, operative indications, port placement, operative time, robot time, complications, and hospital stay were recorded. Follow-up evaluation was appropriate for the individual procedure. RESULTS: Initially, 35 cases were managed. There were 22 anti-reflux procedures, 9 Heller myotomies, 1 pyloroplasty, 1 distal pancreatectomy with splenectomy, 1 esophagectomy with intrathoracic anastomosis, and 1 diagnostic laparoscopy. The operative times ranged from 88 to 458 min. The robot use times were between 16 and 185 min. There were no device-related complications. CONCLUSIONS: Computer-enhanced robotic telesurgery is a safe and effective treatment method for a variety of diseases of the proximal gastrointestinal tract. Further study is needed to determine the benefits of this approach as compared with current technology.

Anastomosis, Surgical↗